Search
Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15788ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Afluria Tetra Injektionssuspension in einer FertigspritzeSodium phosphate, dibasic, unspecified form
go.drugbank.com/drugs/DB14504ApprovedMixtures: Aminosyn II in Dextrose, Aminosyn II with ElectrolytesFosgemcitabine palabenamide
go.drugbank.com/drugs/DB15057InvestigationalNUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).
Synonyms: L-ALANINE, N-(2'-DEOXY-2',2'-DIFLUORO-P-PHENYL-5'-CYTIDYLYL)-, PHENYLMETHYL ESTER, N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-L-alanine phenylmethyl esterNeisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
go.drugbank.com/drugs/DB10284ApprovedInvestigationalIt is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily … Neisseria meningitidis serogroup B recombinant lp2086 a05 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused
Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5MLMeningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.
Mixtures: Mencevax Ac Pws Inj 2500mcg/vial, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADETSQ-109
go.drugbank.com/drugs/DB05186InvestigationalCurrently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen. … SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB.
Synonyms: N-adamantanyl-N'-geranyl-ethylenediamineInfluenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14385ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer FertigspritzeDepemokimab
go.drugbank.com/drugs/DB18846ApprovedInvestigational[A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence. … [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients
Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen
go.drugbank.com/drugs/DB10285ApprovedInvestigationalIt is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily … Neisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused
Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5MLEthinylestradiol
go.drugbank.com/drugs/DB00977ApprovedInvestigationalEthinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability. … [A191107] These properties were achieved by the substitution of an ethinyl group at carbon 17 of [estradiol].[A191107] Ethinylestradiol soon replaced [mestranol] in contraceptive pills.
Mixtures: Lenea 20 µg/75 µg überzogene Tabletten, PIL KB I KOMBINASI